> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Gilead’s Veklury OK’d for Covid Pediatric Patients
- URL: https://www.fdaweb.com/gileads-veklury-okd-for-covid-pediatric-patients/
- Published: 2022-04-25T12:00:00.000Z
- Updated: 2026-09-14T17:41:57.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151671

FDA has expanded the approval of Gilead Sciences’ Veklury (remdesivir) to include treating Covid-19 pediatric patients 28 days of age and older weighing at least 3 kilograms. FDA says the therapy in this population is for those hospitalized, or not hospitalized but at high risk for progression to severe Covid-19, including hospitalization or death, according to an [agency release](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-approves-first-covid-19-treatment-young-children?ref=fdaweb.com). Previously, Veklury was approved to treat certain adults and pediatric patients 12 years of age and older who weigh at least 40 kilograms.